Related Experiment Video
Updated: Nov 16, 2025
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
Validation of Quality Control Parameters of Cassette-Based Gallium-68-DOTA-Tyr3-Octreotate Synthesis
Antonino Sammartano1, Silvia Migliari1, Maura Scarlattei1
1Department of Nuclear Medicine and Molecular Imaging, University Hospital of Parma, Parma, Italy.
Purpose Of The Study:
Gallium (Ga)-68-DOTA peptides targeting somatostatin receptors have been assessed as a valuable tool in neuroendocrine tumor imaging using positron emission tomography. However, at the moment, a specific monograph in the European Pharmacopoeia (Ph. Eur.) does exist only for Ga-68-edotreotide (DOTATOC) injection. Here, we report on the validation process of Ga-68-DOTA-Tyr3-octreotate (DOTATATE) cassette-based production and quality control (QC).
Materials And Methods:
Preparation of Ga-68-DOTATATE was performed according to the current European Union-good manufacturing practices, the current good radiopharmacy practice, the Ph. Eur., and the guidelines on validation of analytical methods for radiopharmaceuticals. Process was validated via three consecutive production runs to ensure that the methods are reproducible and reliable in routine use. The QC tests for Ga-68-DOTATATE were radiochemical purity (RCP - high-pressure liquid chromatography [HPLC]), radiochemical impurities 68Ga3+ (HPLC and instant thin layer chromatography [ITLC]), chemical purity (HPLC and gas chromatography [GC]), pH (pH-strips), radionuclidic purity (principal γ-photon), germanium-breakthrough (68Ge-content), Ga-68 half-life (γ-ray spectrometry), and sterility/endotoxin assay.
Results:
Radiolabeling procedure of Ga-68-DOTATATE fits all the applicable Ph. Eur. specifications. RCP measured via ITLC was >99% in the three validation batches. HPLC-measured RCP resulted 99.45%, 99.78%, and 99.75%. Germanium-breakthrough was far below the recommended level established in the Ph. Eur. Ga-68-DOTATOC injection (#2482). Residual ethanol tested with GC was less than 10%. All the batches were tested for endotoxin content, which always resulted lower than 17.5 EU/ml. All preparations passed the sterility tests. pH of the final product was 7 in all samples.
Conclusion:
Ga-68-DOTATATE fulfilled all the pre-set QCs and release criteria in the batches considered for this validation study. The results demonstrated a batch-to-batch reproducibility, ensuring that synthesis process leads to the expected final product in terms of yield, quality, reliability, safety, and efficacy.
Insights
This study validates the production and quality control of Gallium-68-DOTA-Tyr3-octreotate (Ga-68-DOTATATE) for neuroendocrine tumor imaging. The results confirm its reproducibility and adherence to European Pharmacopoeia standards, ensuring a reliable diagnostic agent.
Area of Science:
- Radiopharmaceutical Chemistry
- Nuclear Medicine
- Analytical Chemistry
Background:
- Gallium-68 (Ga-68) DOTA peptides are crucial for neuroendocrine tumor imaging via positron emission tomography.
- A European Pharmacopoeia (Ph. Eur.) monograph currently exists only for Ga-68-edotreotide (DOTATOC).
Purpose of the Study:
- To validate the cassette-based production and quality control (QC) of Ga-68-DOTA-Tyr3-octreotate (DOTATATE).
- To ensure the reliability and reproducibility of Ga-68-DOTATATE for clinical use.
Main Methods:
- Production of Ga-68-DOTATATE followed Good Manufacturing Practices and Ph. Eur. guidelines.
- Validation involved three consecutive production runs.
- Quality control tests included radiochemical purity (HPLC, ITLC), impurities (HPLC, GC), pH, radionuclidic purity, germanium-breakthrough, and sterility/endotoxin assays.
Main Results:
- Radiolabeling met all applicable Ph. Eur. specifications.
- Radiochemical purity (RCP) exceeded 99% in all validation batches.
- Germanium-breakthrough, residual ethanol, endotoxin levels, and pH were within acceptable limits, and all preparations passed sterility tests.
Conclusions:
- Ga-68-DOTATATE successfully met all predefined quality control and release criteria.
- The validated process ensures batch-to-batch reproducibility, yielding a high-quality, reliable, safe, and effective diagnostic agent.
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
